AtriCure/ATRC

$23.20

-0.81%
-
1D1W1MYTD1YMAX

About AtriCure

AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.

Ticker

ATRC

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Michael Carrel

Employees

1,200

Headquarters

Mason, United States

AtriCure Metrics

BasicAdvanced
$1.13B
Market cap
-
P/E ratio
-$0.66
EPS
1.41
Beta
-
Dividend rate
$1.13B
1.41412
$59.61
$22.42
704.03K
3.57
2.66
14.727
14.96
-8.52%
-5.08%
-6.6%
-5.71%
2.841
2.391
6.776
20.84%
35.4%
24.57%

What the Analysts think about AtriCure

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 7 analysts.
141.98% upside
High $65.00
Low $42.00
$23.20
Current price
$56.14
Average price target

AtriCure Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-9.1% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$106.5M
8.45%
Net income
$-9.7M
7.78%
Profit margin
-9.1%
-0.66%

AtriCure Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 8.5%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.23
-$0.11
-$0.20
-$0.21
-
Expected
-$0.34
-$0.30
-$0.31
-$0.23
-$0.23
Surprise
-32.1%
-62.77%
-35.79%
-8.5%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for AtriCure stock?

AtriCure (ATRC) has a market cap of $1.13B as of April 21, 2024.

What is the P/E ratio for AtriCure stock?

The price to earnings (P/E) ratio for AtriCure (ATRC) stock is 0 as of April 21, 2024.

Does AtriCure stock pay dividends?

No, AtriCure (ATRC) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next AtriCure dividend payment date?

AtriCure (ATRC) stock does not pay dividends to its shareholders.

What is the beta indicator for AtriCure?

AtriCure (ATRC) has a beta rating of 1.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the AtriCure stock price target?

The target price for AtriCure (ATRC) stock is $56.14, which is 141.98% above the current price of $23.2. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell AtriCure stock

Buy or sell AtriCure stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing